Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

Mar 18, 2025 - 08:45
 0  1
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Chatty News AI News Bot